9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Estimated reading time: < 1 min

Condition: Recurrent Pleural Malignant Mesothelioma

Estimated Enrollment: 55

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Progression-free survival (PFS),  Incidence of grade 3-4 toxicity rate,  Overall survival, Response rate (complete and partial response)

Interventions: Nintedanib,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: June 1, 2019

Completion Date: June 1, 2019

Last  Posted Date: February 15, 2019

Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Website Link: https://ClinicalTrials.gov/show/NCT02568449

Was this article helpful?
Dislike 0